1. Executive Summary of the Month
In November, 114 biopharmaceutical agreements were announced worldwide. In China’s biotech sector, there were 19 out-licensing deals, 7 in-licensing deals, and 14 domestic partnerships.
The top out-licensing deal was signed between LTZ Therapeutics and GSK for four first-in-class (FIC) candidates in the preclinical stage, with an upfront payment of $50 million. The top domestic deal was between Laekna Therapeutics and Qilu Pharmaceutical for the Phase III asset afuresertib, with a total deal value of $284 million.
Globally, 74 cross-border deals were reported, with the largest being the agreement between Dr. Falk Pharma and Merck & Co. for the Phase I asset PRA052, which included an upfront payment of $150 million.
2025年11月，全球医药市场共签署了114项资产授权和合作协议。中国市场共达成40项交易，包括19项出海交易、7项引进交易和14项国内交易。
国内市场上，本月最大的出海交易是泽安生物就其四项首创的临床前资产与GSK达成战略合作，首付款5000万美元。本月最大的国内交易是来凯医药与齐鲁制药就临床三期资产afuresertib达成中国地区独家许可协议，总价值可达2.84亿美元。
国际市场上，本周共签署了74项资产授权和合作协议。最大的一项交易是Merck & Co.从Dr. Falk Pharma收回临床一期资产PRA052的共同开发权益，首付款1.5亿美元，以及相关开发里程碑付款和销售分成。
2. Licensing Deals
2a. In-Licensing Deals
2b. Out-Licensing Deals
2c. Domestic Licensing Deals
3. Top Deals of the Year 2025
4. 2019-2024 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong, proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
UPCOMING EVENT:
ACCESS ASIA Asia BD Forum @ JPM 2026, hosted by Jaffa Capital, will be held on January 11, 2026, at the InterContinental San Francisco, concurrently with the globally renowned JP Morgan Healthcare Conference. As a premier cross-border pharmaceutical business exchange and cooperation platform, the ACCESS ASIA PharmaNet Asia BD Forum has been successfully held for six consecutive years, bringing together pharmaceutical companies, biotechnology companies, and investment institutions from around the world to participate in a one-day event, including:
- Corporate Roadshow
- Keynote speech
- Roundtable Forum
- Dialogue with Innovative Enterprises
- One-on-one cooperation negotiation
The forum is committed to connecting Asian biotechnology innovators with international partners and investors, promoting in-depth cross-border cooperation, licensing opportunities, and strategic dialogue.
👉 Click to learn more:🔗 https://biotochina.org/
📢 Stay tuned for more guest and agenda updates:🔗 https://biotochina.org/agenda/
Registration
BioToChina.org 
